Trial Profile
Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- 13 Mar 2018 Status changed from recruiting to completed.
- 04 Nov 2015 New trial record